SPOILERS: This post contains details about the White Lotus, Season 3 episode ‘Denials’ As this season of The White Lotus continues to push the limits of Mike White’s imagination, a ...

The university claims using the logo in the scene "simply goes too far." By Lexi Carson [The following story contains spoilers from the latest episode of The White Lotus, “Denials.”] ...

It’s not HBO, it’s Max — but the new standalone logo for Warner Bros. Discovery‘s streamer now certainly looks like HBO’s at a glance. The Max streaming service has quietly launched a ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

(L-R) Mike White and Cristóbal Tapia de Veer Getty/Michael Buckner for Deadline The White Lotus creator Mike White is striking back at composer Cristóbal Tapia de Veer‘s claims about fights ...

The White House moved the official portrait of former President Barack Obama to a new location in the building’s Grand Foyer, replacing it with a painting of President Donald Trump with his fist ...

As this season of The White Lotus continues to push the limits of Mike White’s imagination, a particular subset of the audience is not happy. Following last week’s Season 3 episode ‘Denials ...

Duke didn’t approve the use of its logo in The White Lotus, the school said in response to questions from Bloomberg. “The White Lotus not only uses our brand without permission, but in our ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

As this season of The White Lotus continues to push the limits of Mike White’s imagination, a particular subset of the audience is not happy. Following last week’s Season 3 episode ‘Denials’, in which ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. Discover outperforming stocks and invest smarter with ...